© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Genitourinary Drugs Market trends research and projections for : Global Market Insights Inc.

© 2016 Global Market Insights, Inc. USA. All Rights Reserved  U.S. genitourinary drugs market size held a large share of the global genitourinary drugs in 2015 due to robust healthcare infrastructure, growing awareness, and technological advancements in the development of genitourinary drugs.  Canada genitourinary drugs market share is driving due to the burden of cancer disease in the country. As per the Canadian Cancer Statistics in 2015, about 196,900 people diagnosed with cancer.The data is important to focus on prevention efforts, in both primary prevention and secondary prevention of cancer, and allow more effective treatment of certain cancer through earlier detection.  Europe genitourinary drugs market will witness a significant growth over the forecast timeframe. It was estimated that over 78% of the new cancer medicines that were introduced between 2010 and 2014 are available within the greater EU. In 2012, Germany’s GDP accounted for over USD 34,706.8 per capita, driving the industry growth. Regional Analysis of Genitourinary Drugs Market :

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Application Analysis of Genitourinary Drugs Market :  Prostate cancer contributed to over 25% revenue share in A wide range of therapeutics, such as radiopharmaceuticals, immunotherapy medication, and anti-neoplastic agents, available to treat prostate cancer will drive this segment’s growth. According to National Cancer Institute (NCI), the total number of new prostate cancer cases between 2009 to 2013 were per 100,000 men every year.  Urinary Tract Infections (UTIs) affect more than 150 million people every year worldwide, resulting in direct healthcare expenses of over USD 6 billion. Around 2.4 percent of women and men will be detected with bladder cancer at some point during their lifetime.

© 2016 Global Market Insights, Inc. USA. All Rights Reserved  Companies are focusing on the implementation of strategies including mergers & acquisitions, new product development, and regional expansion. In October 2016, the U.S. FDA approved a supplemental Biologics License Application (sBLA) of Bristol-Myers Squibb, to enlarge the practice of Opdivo (nivolumab) to treat patients suffering from an advanced form of bladder cancer. Similarly, in June 2016, the U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP) and Bayer, collaborated on a new Phase III trial to study Stivarga (regorafenib) tablets as an adjuvant therapy in colon cancer. Growing geographical presence of the industry players is expected to raise the awareness levels regarding treatment options for genitourinary diseases among the patients and the doctors. Competitive Market Share of Genitourinary Drugs Market :

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Browse Full Market Research Report On Genitourinary Drugs Request for an in-depth table of contents for this Gaming Console Market

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Stay In Touch Website: Social Media: